Zusammenfassung
Kondylome sind bei HIV-infizierten Patienten wesentlich häufiger als bei HIV-negativen Personen. Kondylome HIV-Positiver unterscheiden sich von denen HIV-Negativer in der Ausdehnung, im Auftreten an ungewöhnlicheren Lokalisationen, im HPV (humane Papillomviren)-Typenspektrum, in der Rezidivneigung sowie im Entartungsrisiko. Etwa 18–56 % der Kondylome HIV-positiver Patienten enthalten hochgradige Dysplasien. Aus diesem Grund sollten Kondylome bei HIV-Infizierten vorzugsweise ablativ entfernt und histopathologisch evaluiert werden. Durch die geschlechtsneutrale prophylaktische HPV-Impfung von HPV-naiven Jungen und Mädchen könnte zukünftig eine deutliche Reduktion von Kondylomen auch in dieser Patientengruppe erreicht werden.
Abstract
Anogenital warts (condylomata acuminata) are much more frequent in human immunodeficiency (HIV)-positive patients compared to HIV-negative individuals. Anogenital warts of HIV-infected patients differ from those of HIV-negative individuals with respect to their spread, occurrence on more unusual anatomical sites, human papillomavirus (HPV)-type spectrum, tendency to recur, and risk of malignant transformation. Between 18 and 56% of anogenital warts of HIV-positive patients harbor high-grade dysplasia. Therefore, anogenital warts of HIV-infected patients should be preferentially treated with ablative methods and should be evaluated histopathologically. Gender-neutral prophylactic HPV vaccination of HPV-naive boys and girls could also lead to a significant reduction of anogenital warts in this patient group in the future.
Literatur
Abramowitz L, Benabderrahmane D, Ravaud P et al (2007) Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: Prevalence and associated factors. AIDS 21:1457–1465
Ali H, Donovan B, Wand H et al (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: National surveillance data. BMJ 346:f2032
Bhageerathy PS, Cecilia M, Sebastian A et al (2014) Human papilloma virus-16 causing giant condyloma acuminata. J Surg Case Rep. doi:10.1093/jscr/rjt126
Braun SA, Jansen TM, Homey B et al (2015) Successful therapy of condylomata acuminata with ingenol mebutate. Hautarzt 66:223–225
Chirgwin KD, Feldman J, Augenbraun M et al (1995) Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women. J Infect Dis 172:235–238
Coskuner ER, Ozkan TA, Karakose A et al (2014) Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: A randomized study. J Sex Med 11:2785–2791
De Camargo CC, Tasca KI, Mendes MB et al (2014) Prevalence of anogenital warts in men with HIV/AIDS and associated factors. Open AIDS J 8:25–30
Dinleyici M, Saracoglu N, Eren M et al (2015) Giant Condyloma Acuminate due to human Papillomavirus type 16 in an infant successfully treated with topical Imiquimod therapy. Dermatol Reports 7:6134
Dolev JC, Maurer T, Springer G et al (2008) Incidence and risk factors for verrucae in women. AIDS 22:1213–1219
Drolet M, Benard E, Boily MC et al (2015) Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis 15:565–580
Dupin N (2004) Genital warts. Clin Dermatol 22:481–486
Esser S, Kreuter A, Oette M et al (2015) German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: Prevention, diagnosis, and treatment. J Dtsch Dermatol Ges 13:1302–1319
Fuchs W, Wieland U, Skaletz-Rorowski A et al (2016) The male ScreenING Study: Prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany. J Eur Acad Dermatol Venereol 30:995–1001
Giuliano AR, Palefsky JM, Goldstone S et al (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364:401–411
Gormley RH, Kovarik CL (2012) Human papillomavirus-related genital disease in the immunocompromised host: Part I. J Am Acad Dermatol 66(867):e861–e814
Gormley RH, Kovarik CL (2012) Human papillomavirus-related genital disease in the immunocompromised host: Part II. J Am Acad Dermatol 66(883):e881–e817
Grussendorf-Conen EI (1997) Anogenital premalignant and malignant tumors (including Buschke-Lowenstein tumors). Clin Dermatol 15:377–388
Hernandez-Suarez G, Pineros M, Vargas JC et al (2013) Human papillomavirus genotypes in genital warts in Latin America: a cross-sectional study in Bogota, Colombia. Int J STD AIDS 24:567–572
Hildesheim A, Gonzalez P, Kreimer AR et al (2016) Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol 215:212
Jiamton S, Leeyaphan C, Maneeprasopchoke P et al (2014) Prevalence and clinical manifestations of male patients with Anogenital warts attending a sexually transmitted disease clinic prior Hpv vaccine recommendation. Southeast Asian J Trop Med Public Health 45:1337–1343
Komlos KF, Kocjan BJ, Kosorok P et al (2012) Tumor-specific and gender-specific pre-vaccination distribution of human papillomavirus types 6 and 11 in anogenital warts and laryngeal papillomas: A study on 574 tissue specimens. J Med Virol 84:1233–1241
Kraut AA, Schink T, Schulze-Rath R et al (2010) Incidence of anogenital warts in Germany: A population-based cohort study. BMC Infect Dis 10:360
Kreuter A, Siorokos C, Oellig F et al (2016) High-grade Dysplasia in anogenital warts of HIV-positive men. JAMA Dermatol 152:1225–1230
Kreuter A, Wieland U (2013) Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. J Am Acad Dermatol 68:179–180
Maniar KP, Ronnett BM, Vang R et al (2013) Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: Independent lesions due to different HPV types occurring in immunocompromised patients. Am J Surg Pathol 37:53–60
Mccloskey JC, Metcalf C, French MA et al (2007) The frequency of high-grade intraepithelial neoplasia in anal/perianal warts is higher than previously recognized. Int J STD AIDS 18:538–542
Patel H, Wagner M, Singhal P et al (2013) Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 13:39
Pimenoff VN, Felez-Sanchez M, Tous S et al (2015) Disagreement in high-grade/low-grade intraepithelial neoplasia and high-risk/low-risk HPV infection: Clinical implications for anal cancer precursor lesions in HIV-positive and HIV-negative MSM. Clin Microbiol Infect 21(605):e611–e609
Richel O, Hallensleben ND, Kreuter A et al (2013) High-resolution anoscopy: Clinical features of anal intraepithelial neoplasia in HIV-positive men. Dis Colon Rectum 56:1237–1242
Robert-Koch-Institut (2016) Anwendung des neunvalenten Impfstoffs gegen Humane Papillomviren (HPV). Epidemiol Bull 16:137
Robert Koch-Institut (2016) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiol Bull 34:312
Schiller JT, Lowy DR (2012) Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 10:681–692
Schiller JT, Müller M (2015) Next generation prophylactic human papillomavirus vaccines. Lancet Oncol 16:e217–e225
Schopf RE (2016) Ingenol mebutate gel is effective against anogenital warts – a case series in 17 patients. J Eur Acad Dermatol Venereol 30:1041–1043
Siegenbeek Van Heukelom ML, Richel O, De Vries HJ et al (2016) Low- and high-risk human papillomavirus genotype infections in intra-anal warts in HIV-positive men who have sex with men. Br J Dermatol 175:735–743
Snoeck R, Bossens M, Parent D et al (2001) Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 33:597–602
Stanley M (2012) Perspective: Vaccinate boys too. Nature 488:S10
Stier EA, Goldstone SE, Einstein MH et al (2013) Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS 27:545–551
Sturegard E, Johansson H, Ekstrom J et al (2013) Human papillomavirus typing in reporting of condyloma. Sex Transm Dis 40:123–129
Swedish KA, Factor SH, Goldstone SE (2012) Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 54:891–898
Wieland U, Kreuter A (2011) HPV vaccine against HPV infection and disease in males. N Engl J Med 364:2163
Wikstrom A, Vassilaki I, Hedblad MA et al (2013) The spectrum of genital human papillomavirus infection among men attending a Swedish sexually-transmitted infections clinic: Human papillomavirus typing and clinical presentation of histopathologically benign lesions. Acta Derm Venereol 93:223–227
Wilkin TJCH, Cespedes M et al (2016) ACTG A5298: A phase 3 trail of quadrivalent HPV vaccine in older HIV+ adults. Conference on Retroviruses and Opportunistic Infections (CROI) Abstract 161. http://www.croiconference.org/scientific-program/electronic-materials/croi-2016. Zugegriffen: 05.01.2017
Workowski KA, Bolan GACDC (2015) Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64:1–137
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
U. Wieland gibt an, dass kein Interessenkonflikt besteht. A. Kreuter hat Referentenhonorare von Sanofi Pasteur MSD erhalten und war im Advisory Board von Sanofi Pasteur MSD tätig.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Wieland, U., Kreuter, A. Kondylome bei HIV-Infizierten. Hautarzt 68, 192–198 (2017). https://doi.org/10.1007/s00105-017-3938-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-017-3938-z